The impact of ageing on the barriers to drug delivery

Yvonne Perrie, Raj Singh Badhan, Daniel J. Kirby, Deborah Lowry, Afzal-Ur-Rahman Mohammed, Defang Ouyang

Research output: Contribution to journalArticle

Abstract

Generally, we like to see ageing as a process that is happening to people older than ourselves. However the process of ageing impacts on a wide range of functions within the human body. Whilst many of the outcomes of ageing can now be delayed or reduced, age-related changes in cellular, molecular and physiological functionality of tissues and organs can also influence how drugs enter, distribute and are eliminated from the body. Therefore, the changing profile of barriers to drug delivery should be considered if we are to develop more age-appropriate medicines. Changes in the drug dissolution and absorption in older patients may require the formulation of oral delivery systems that offer enhanced retention at absorption sites to improve drug delivery. Alternatively, liquid and fast-melt dosage systems may address the need of patients who have difficulties in swallowing medication. Ageing-induced changes in the lung can also result in slower drug absorption, which is further compounded by disease factors, common in an ageing population, that reduce lung capacity. In terms of barriers to drug delivery to the eye, the main consideration is the tear film, which like other barriers to drug delivery, changes with normal ageing and can impact on the bioavailability of drugs delivery using eye drops and suspensions. In contrast, whilst the skin as a barrier changes with age, no significant difference in absorption of drugs from transdermal drug delivery is observed in different age groups. However, due to the age-related pharmacokinetic and pharmacodynamic changes, dose adaptation should still be considered for drug delivery across the skin. Overall it is clear that the increasing age demographic of most populations, presents new (or should that be older) barriers to effective drug delivery. © 2012 Elsevier B.V. All rights reserved.
LanguageEnglish
Pages389-398
Number of pages10
JournalJournal of Controlled Release
Volume161
Issue number2
Early online date24 Jan 2012
DOIs
Publication statusPublished - 20 Jul 2012

Fingerprint

Pharmaceutical Preparations
Lung Volume Measurements
Skin Absorption
Skin
Ophthalmic Solutions
Deglutition
Tears
Human Body
Population
Biological Availability
Suspensions
Pharmacokinetics
Age Groups
Demography
Lung

Keywords

  • drug delivery
  • ageing
  • oral route
  • pulmonary route
  • topical delivery
  • ocular route

Cite this

@article{dc6fa2ca2ce740fe9f382b75eeb7d1c2,
title = "The impact of ageing on the barriers to drug delivery",
abstract = "Generally, we like to see ageing as a process that is happening to people older than ourselves. However the process of ageing impacts on a wide range of functions within the human body. Whilst many of the outcomes of ageing can now be delayed or reduced, age-related changes in cellular, molecular and physiological functionality of tissues and organs can also influence how drugs enter, distribute and are eliminated from the body. Therefore, the changing profile of barriers to drug delivery should be considered if we are to develop more age-appropriate medicines. Changes in the drug dissolution and absorption in older patients may require the formulation of oral delivery systems that offer enhanced retention at absorption sites to improve drug delivery. Alternatively, liquid and fast-melt dosage systems may address the need of patients who have difficulties in swallowing medication. Ageing-induced changes in the lung can also result in slower drug absorption, which is further compounded by disease factors, common in an ageing population, that reduce lung capacity. In terms of barriers to drug delivery to the eye, the main consideration is the tear film, which like other barriers to drug delivery, changes with normal ageing and can impact on the bioavailability of drugs delivery using eye drops and suspensions. In contrast, whilst the skin as a barrier changes with age, no significant difference in absorption of drugs from transdermal drug delivery is observed in different age groups. However, due to the age-related pharmacokinetic and pharmacodynamic changes, dose adaptation should still be considered for drug delivery across the skin. Overall it is clear that the increasing age demographic of most populations, presents new (or should that be older) barriers to effective drug delivery. {\circledC} 2012 Elsevier B.V. All rights reserved.",
keywords = "drug delivery, ageing, oral route, pulmonary route, topical delivery, ocular route",
author = "Yvonne Perrie and {Singh Badhan}, Raj and Kirby, {Daniel J.} and Deborah Lowry and Afzal-Ur-Rahman Mohammed and Defang Ouyang",
year = "2012",
month = "7",
day = "20",
doi = "10.1016/j.jconrel.2012.01.020",
language = "English",
volume = "161",
pages = "389--398",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

The impact of ageing on the barriers to drug delivery. / Perrie, Yvonne; Singh Badhan, Raj; Kirby, Daniel J.; Lowry, Deborah; Mohammed, Afzal-Ur-Rahman; Ouyang, Defang.

In: Journal of Controlled Release, Vol. 161, No. 2, 20.07.2012, p. 389-398.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The impact of ageing on the barriers to drug delivery

AU - Perrie, Yvonne

AU - Singh Badhan, Raj

AU - Kirby, Daniel J.

AU - Lowry, Deborah

AU - Mohammed, Afzal-Ur-Rahman

AU - Ouyang, Defang

PY - 2012/7/20

Y1 - 2012/7/20

N2 - Generally, we like to see ageing as a process that is happening to people older than ourselves. However the process of ageing impacts on a wide range of functions within the human body. Whilst many of the outcomes of ageing can now be delayed or reduced, age-related changes in cellular, molecular and physiological functionality of tissues and organs can also influence how drugs enter, distribute and are eliminated from the body. Therefore, the changing profile of barriers to drug delivery should be considered if we are to develop more age-appropriate medicines. Changes in the drug dissolution and absorption in older patients may require the formulation of oral delivery systems that offer enhanced retention at absorption sites to improve drug delivery. Alternatively, liquid and fast-melt dosage systems may address the need of patients who have difficulties in swallowing medication. Ageing-induced changes in the lung can also result in slower drug absorption, which is further compounded by disease factors, common in an ageing population, that reduce lung capacity. In terms of barriers to drug delivery to the eye, the main consideration is the tear film, which like other barriers to drug delivery, changes with normal ageing and can impact on the bioavailability of drugs delivery using eye drops and suspensions. In contrast, whilst the skin as a barrier changes with age, no significant difference in absorption of drugs from transdermal drug delivery is observed in different age groups. However, due to the age-related pharmacokinetic and pharmacodynamic changes, dose adaptation should still be considered for drug delivery across the skin. Overall it is clear that the increasing age demographic of most populations, presents new (or should that be older) barriers to effective drug delivery. © 2012 Elsevier B.V. All rights reserved.

AB - Generally, we like to see ageing as a process that is happening to people older than ourselves. However the process of ageing impacts on a wide range of functions within the human body. Whilst many of the outcomes of ageing can now be delayed or reduced, age-related changes in cellular, molecular and physiological functionality of tissues and organs can also influence how drugs enter, distribute and are eliminated from the body. Therefore, the changing profile of barriers to drug delivery should be considered if we are to develop more age-appropriate medicines. Changes in the drug dissolution and absorption in older patients may require the formulation of oral delivery systems that offer enhanced retention at absorption sites to improve drug delivery. Alternatively, liquid and fast-melt dosage systems may address the need of patients who have difficulties in swallowing medication. Ageing-induced changes in the lung can also result in slower drug absorption, which is further compounded by disease factors, common in an ageing population, that reduce lung capacity. In terms of barriers to drug delivery to the eye, the main consideration is the tear film, which like other barriers to drug delivery, changes with normal ageing and can impact on the bioavailability of drugs delivery using eye drops and suspensions. In contrast, whilst the skin as a barrier changes with age, no significant difference in absorption of drugs from transdermal drug delivery is observed in different age groups. However, due to the age-related pharmacokinetic and pharmacodynamic changes, dose adaptation should still be considered for drug delivery across the skin. Overall it is clear that the increasing age demographic of most populations, presents new (or should that be older) barriers to effective drug delivery. © 2012 Elsevier B.V. All rights reserved.

KW - drug delivery

KW - ageing

KW - oral route

KW - pulmonary route

KW - topical delivery

KW - ocular route

UR - http://www.scopus.com/inward/record.url?scp=84862691464&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.01.020

DO - 10.1016/j.jconrel.2012.01.020

M3 - Article

VL - 161

SP - 389

EP - 398

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -